[1]郑献敏,王辉,徐剑峰,等.羌活补阳还五汤治疗血瘀证急性期类风湿关节炎的疗效及对血小板活化的影响[J].中国中医骨伤科杂志,2025,33(08):61-65.[doi:10.20085/j.cnki.issn1005-0205.250811]
　ZHENG Xianmin,WANG Hui,XU Jianfeng,et al.The Efficacy of Qianghuo Buyang Huanwu Decoction in Treating Rheumatoid Arthritis with Blood Stasis Syndrome in the Acute Stage and Its Impact on Platelet Activation[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2025,33(08):61-65.[doi:10.20085/j.cnki.issn1005-0205.250811]
点击复制

羌活补阳还五汤治疗血瘀证急性期类风湿关节炎的疗效及对血小板活化的影响()

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第33卷
期数:
2025年08期
页码:
61-65
栏目:
临床研究
出版日期:
2025-08-15

文章信息/Info

Title:
The Efficacy of Qianghuo Buyang Huanwu Decoction in Treating Rheumatoid Arthritis with Blood Stasis Syndrome in the Acute Stage and Its Impact on Platelet Activation
文章编号:
1005-0205(2025)08-0061-05
作者:
郑献敏1; 王辉1; 徐剑峰1; 钟晓琴1; 徐泽军1; 马洁1
1深圳市宝安中医院(集团)(广东 深圳,518133)
Author(s):
ZHENG Xianmin1; WANG Hui1; XU Jianfeng1; ZHONG Xiaoqin1; XU Zejun1; MA Jie1
1Shenzhen Bao'an Traditional Chinese Hospital(Group),Shenzhen 518133,Guangdong China.
关键词:
类风湿关节炎;  羌活补阳还五汤;  血小板活化;  急性期
Keywords:
rheumatoid arthritis;  Qianghuo Buyang Huanwu decoction;  platelet activation;  acute phase
分类号:
R684.3
DOI:
10.20085/j.cnki.issn1005-0205.250811
文献标志码:
A
摘要:
目的:探讨羌活补阳还五汤治疗血瘀证急性期类风湿关节炎(RA)患者的疗效及对血小板活化的影响。方法:选取2021年8月至2024年7月诊治的140例急性期类风湿关节炎患者,随机将其均分为对照组和中药组(各70例)。中药组采用羌活补阳还五汤治疗,对照组口服艾拉莫德和甲氨蝶呤。比较分析两组患者疗效、中医证候评分、28个关节疾病活动度(DAS28)评分、患者健康评定量表(HAQ)评分、长链非编码RNA Uc.48+(LncRNA Uc.48+)表达、不良反应发生率及血小板活化相关指标,并利用体外细胞实验探究其治疗机制。结果:治疗后,中药组总有效率高于对照组,中医证候评分、DAS28评分、HAQ评分均低于对照组,LncRNA Uc.48+、P2Y12、CD62P和PAC-1表达均低于对照组,差异有统计学意义(P<0.05)。中药组总不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。细胞中药干预组LncRNA Uc.48+、P2Y12、CD62P和PAC-1表达均低于细胞LncRNA Uc.48+高表达组,差异有统计学意义(P<0.05)。结论:羌活补阳还五汤治疗血瘀证急性期类风湿关节炎疗效佳且安全性良好,其抑制血小板活化的机制可能与下调LncRNA Uc.48+降低P2Y12表达有关。
Abstract:
Objective:To investigate the efficacy of Qianghuo Buyang Huanwu decoction in the treatment of acute rheumatoid arthritis(RA)with blood stasis syndrome and its impact on platelet activation.Methods:A total of 140 patients with acute RA treated from August 2021 to July 2024 were enrolled and randomly divided into control group and traditional Chinese medicine(TCM)group(n=70).The TCM group was treated with Qianghuo Buyang Huanwu decoction.The control group was treated with iguratimod and methotrexate.The efficacy,TCM syndrome score,DAS28 score,HAQ score,expression of long non-coding RNA Uc.48+(LncRNA Uc.48+),incidence of adverse reactions and related indicators of platelet activation were compared between the two groups.In vitro cell experiments were used to explore its therapeutic mechanism.Results:After treatment,the total effective rate of the TCM group was higher than that of the control group.The TCM syndrome score,DAS28 and HAQ score of the TCM group were lower than those of the control group.The expression of LncRNA Uc.48+,P2Y12,CD62P and PAC-1 in the TCM group were lower than those in the control group(P<0.05).There was no significant difference in the total adverse reaction rate between the TCM group and the control group(P>0.05).The expressions of LncRNA Uc.48+,P2Y12,CD62P and PAC-1 in the cellular TCM group were lower than those in the cellular LncRNA Uc.48+.Conclusion:Qianghuo Buyang Huanwu decoction is effective and safe in the treatment of RA with acute blood stasis syndrome.The mechanism by which Qianghuo Buyang Huanwu decoction inhibits platelet activation may be related to down-regulating LncRNA Uc.48+ and down-regulating P2Y12 expression.

参考文献/References:

[1] 《中医康复临床实践指南·类风湿关节炎》制定工作组.中医康复临床实践指南·类风湿关节炎[J].康复学报,2020,30(1):16-25.
[2] 汤晓菲,李永红,丁秋玲,等.类风湿关节炎患者下肢深静脉血栓发病率及危险因素[J].北京大学学报(医学版),2024,56(2):279-283.
[3] PENG L,WU B,SHI L,et al.Long non-coding RNA Uc.48+ small interfering RNA alleviates neuroinflammatory hyperalgesia in Gp120-treated rats via the P2Y12 receptor[J].Front Neurosci,2021,15:663962.
[4] 刘景新,陈余兴,王贵.LncRNA Uc.48+通过激活P2X7R/NF-κB通路促进骨关节炎软骨组织的炎症[J].河北医学,2022,28(2):213-219.
[5] 中华医学会风湿病学分会.2018中国类风湿关节炎诊疗指南[J].中华内科杂志,2018,57(4):242-251.
[6] 李云,张强,吕婧,等.类风湿关节炎患者中医体质分布特点及其与血清TNF-α、25(OH)D水平的关系[J].四川中医,2024,42(4):95-100.
[7] 冯月男,牛雯颖,张玉昆,等.基于血小板活化和炎症相关指标探讨补阳还五汤对气虚血瘀证调控机制的研究[J].时珍国医国药,2023,34(3):581-584.
[8] MENICHELLI D,CORMACI V M,MARUCCI S,et al.Risk of venous thromboembolism in autoimmune diseases:a comprehensive review[J].Autoimmun Rev,2023,22(11):103447.
[9] 邹来勇,涂国卿,汤群珍.旴江医家“治风先治血”思想探骊[J].中国中医基础医学杂志,2019,25(5):585-586.
[10] 张慧月,刘洋洋,孙磊,等.基于网络药理学与分子对接方法探讨羌活胜湿汤治疗类风湿关节炎的作用机制[J].中国医院用药评价与分析,2023,23(12):1426-1432.
[11] 罗来兵.补阳还五汤联合舒筋外洗颗粒治疗膝骨性关节炎气虚血瘀证临床观察[J].中国中医药现代远程教育,2021,19(21):91-93.
[12] STANGER L,YAMAGUCHI A,YALAVARTHI P,et al.The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor[J].Blood,2023,142(18):1556-1569.
[13] JIANG Z,JIANG X,CHEN A,et al.Platelet activation:a promoter for psoriasis and its comorbidity,cardiovascular disease[J].Front Immunol,2023,14:1238647.
[14] BOILARD E,NIGROVIC P A,LARABEE K,et al.Platelets amplify inflammation in arthritis via collagen-dependent microparticle production[J].Science,2010,327(5965):580-583.
[15] 严婕,李琴,朱光昭,等.LncRNA SNHG16靶向miR-425-5p对类风湿关节炎滑膜成纤维细胞增殖和凋亡的影响[J].中国细胞生物学学报,2023,45(11):1614-1622.
[16] WU H,WEN F,JIANG M,et al.LncRNA Uc.48+ is involved in the diabetic immune and inflammatory responses mediated by P2X7 receptor in RAW264.7 macrophages[J].Int J Mol Med,2018,42(2):1152-1160.
[17] 沈丽娟,吴锡平,关云艳,等.不同剂量黄芪对脓毒症患者免疫功能和血小板活化因子的干预研究[J].南京中医药大学学报,2019,35(2):135-138.
[18] 欧阳辉发,王友琴,赵淋仙,等.濒危药材羌活化学成分、药理作用、药代动力学研究进展及其应用分析[J].中药与临床,2023,14(4):105-111.
[19] 韩运宗,陈思清,刘琴,等.黄芪建中汤对脾胃虚寒证胃溃疡大鼠炎症因子及HGF/c-Met信号通路的影响[J].中国中医急症,2024,33(1):22-26.
[20] 宋文婷,丁昭,苗兰,等.补阳还五汤治疗大鼠气虚血瘀型脑缺血的代谢组学研究[J].世界中医药,2023,18(15):2154-2159.
[21] 高佳明,郭浩,张业昊,等.补阳还五汤调控急性心肌梗死大鼠血小板自噬保护缺血心肌的作用机制研究[J].中国中药杂志,2023,48(15):4156-4163.
[22] 卞敬琦,张玉昆,冯月男,等.补阳还五汤对高脂血症大鼠血液流变学和血小板聚集作用的影响[J].中国医药导报,2021,18(28):40-43.
[23] ZOU L F,LIU S M,LI L,et al.Implication of P2Y12 receptor in Uc.48+-mediated abnormal sympathoexcitatory reflex via superior cervical ganglia in myocardial ischemic rats[J].Eur J Pharmacol,2022,927:175049.

备注/Memo

备注/Memo:
基金项目:深圳市宝安区科技创新局基础研究项目(2022JD218)
更新日期/Last Update: 2025-08-15